Kane Biotech Statistics

Total Valuation

Kane Biotech has a market cap or net worth of CAD 6.36 million. The enterprise value is 7.77 million.

Market Cap	6.36M
Enterprise Value	7.77M

Important Dates

The next estimated earnings date is Tuesday, May 5, 2026.

Earnings Date	May 5, 2026
Ex-Dividend Date	n/a

Share Statistics

Kane Biotech has 181.86 million shares outstanding. The number of shares has increased by 4.40% in one year.

Current Share Class	181.86M
Shares Outstanding	181.86M
Shares Change (YoY)	+4.40%
Shares Change (QoQ)	-46.46%
Owned by Insiders (%)	43.95%
Owned by Institutions (%)	n/a
Float	101.93M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	14.88
PB Ratio	-8.53
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.85
EV / Sales	18.15
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.38

Financial Position

The company has a current ratio of 0.68

Current Ratio	0.68
Quick Ratio	0.38
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.71
Interest Coverage	-10.75

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-62.39%
Return on Invested Capital (ROIC)	-155.05%
Return on Capital Employed (ROCE)	-1,123.94%
Weighted Average Cost of Capital (WACC)	6.31%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.16
Inventory Turnover	0.97

Taxes

Income Tax	-108,005
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -63.16% in the last 52 weeks. The beta is 0.24, so Kane Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.24
52-Week Price Change	-63.16%
50-Day Moving Average	0.04
200-Day Moving Average	0.04
Relative Strength Index (RSI)	52.25
Average Volume (20 Days)	131,803

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Kane Biotech had revenue of CAD 427,869 and -2.72 million in losses. Loss per share was -0.02.

Revenue	427,869
Gross Profit	-640
Operating Income	-2.61M
Pretax Income	-2.83M
Net Income	-2.72M
EBITDA	-2.55M
EBIT	-2.61M
Loss Per Share	-0.02

Full Income Statement

Balance Sheet

The company has 901,698 in cash and 2.30 million in debt, giving a net cash position of -1.40 million or -0.01 per share.

Cash & Cash Equivalents	901,698
Total Debt	2.30M
Net Cash	-1.40M
Net Cash Per Share	-0.01
Equity (Book Value)	-746,545
Book Value Per Share	-0.00
Working Capital	-812,619

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -3.26 million and capital expenditures -4,895, giving a free cash flow of -3.26 million.

Operating Cash Flow	-3.26M
Capital Expenditures	-4,895
Depreciation & Amortization	61,466
Net Borrowing	665,738
Free Cash Flow	-3.26M
FCF Per Share	-0.02

Full Cash Flow Statement

Margins

Gross Margin	-0.15%
Operating Margin	-609.87%
Pretax Margin	-661.24%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kane Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.40%
Shareholder Yield	-4.40%
Earnings Yield	-42.75%
FCF Yield	-51.22%

Stock Splits

The last stock split was on March 13, 2017. It was a reverse split with a ratio of 0.2.

Last Split Date	Mar 13, 2017
Split Type	Reverse
Split Ratio	0.2

Scores

Kane Biotech has an Altman Z-Score of -20.62 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-20.62
Piotroski F-Score	2